Search This Blog

Tuesday, 24 July 2012

Drs Neurosurgeon 's Worldwide


Dr's NS, treating Tarlov Cyst Patients Worldwide

    Lumbar Epidural Steroid Injections for Low Back Pain and Sciatica

    Lumbar Epidural Steroid Injections for Low Back Pain and Sciatica

    Wednesday, 18 July 2012

    Prevalence of Sacral Spinal (Tarlov) Cysts in Persistent Genital Arousal Disorder.


     2012 May 17. doi: 10.1111/j.1743-6109.2012.02765.x. [Epub ahead of print]

    Prevalence of Sacral Spinal (Tarlov) Cysts in Persistent Genital Arousal Disorder.

    Source

    Department of Psychology, Rutgers, The State University of New Jersey, Newark, NJ, USA Department of Radiology, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA.

    Abstract

    Introduction.  Neither consistent etiology nor treatment have been established for Persistent Genital Arousal Disorder (PGAD), which is characterized by uninvited, unwelcome, and distressing genital sensation. Sacral (Tarlov) cysts, which form on dorsal (sensory) roots, most commonly of S2 and S3 in the sacral spine, are reported to produce genital symptoms that bear similarities to those described for PGAD. Aims.  The present study ascertained the incidence of Tarlov cysts in the sacral spine of women with PGAD symptoms. Methods.  Women in a PGAD internet support group were asked to submit MRIs of their sacral region to the investigators, who evaluated the MRIs for the presence or absence of Tarlov cysts. Main Outcome Measures.  The presence or absence of Tarlov cysts at the level of the sacral spine. Results.  Tarlov cysts were present in 12 of the first 18 (66.7%) MRIs submitted to the investigators by women who suffer from PGAD symptoms. By contrast to this incidence, that of Tarlov cysts reported in the literature for large samples of the population observed for various disorders (e.g., lumbosacral pain) is 1.2-9.0%. Conclusion.  Tarlov cysts have been described in the literature as producing paresthesias and genital sensory disturbances. Hence, at least some cases of PGAD might be considered to be a Tarlov cyst-induced paresthesia. Based on the relatively high occurrence of Tarlov cysts currently observed in women who suffer from PGAD symptoms, it would seem advisable to suspect Tarlov cysts as a possible organic etiological factor underlying PGAD. Komisaruk BR and Lee H-J. Prevalence of sacral spinal (Tarlov) cysts in persistent genital arousal disorder. J Sex Med **;**:**-**.
    © 2012 International Society for Sexual Medicine.
    PMID:
     
    22594432
     
    [PubMed - as supplied by publisher]

    Tuesday, 10 July 2012

    July 2012 – Pain Product Announcements & Warnings


    Tuesday, July 3, 2012

    July 2012 – Pain Product Announcements & Warnings

    AnnouncementsFeatured Items: pregabalin (Lyrica) approved for neuropathic pain in spinal cord injury; gabapentin enacarbil (Horizant) approved for postherpetic neuralgia; OPANA ER conversion to crush-resistant tablets; supplement Reumofan-Plus recalled for undeclared drugs.
    — All brand names are trademarks of their respective manufacturers. Compiled by Winnie Dawson, MA, RN, BSN.

    Pregabalin (Lyrica® Capsules CV) - Approved for Neuropathic Pain Associated with Spinal Cord Injury U.S. Food and Drug Administration officials gave Pfizer a June 2012 approval to market Lyrica Capsules CV for the management of neuropathic pain associated with spinal cord injury. A priority review was granted for this indication following 2 randomized, double blind trials in more than 350 patients comparing flexibly-dosed pregabalin — 150 mg/d to 600 mg/d — with placebo. The studies, which primarily treated patients with traumatic spinal cord injuries, also included a small number of nontraumatic spine-injured patients. Results showed significant reductions in neuropathic pain between baseline and trial end (12 or 16 weeks depending on the study protocol) for treated patients compared with those receiving placebo. Some treated patients experienced significant pain relief at week 1 that continued throughout the trial, and more patients receiving pregabalin reported 30% to 50% reductions in pain than placebo participants. Treatment was also associated with improved sleep and reduced anxiety. Common adverse effects for pregabalin were somnolence, dizziness, dry mouth, fatigue, and peripheral edema. Healthcare providers should advise patients that antiepileptic drugs, including pregabalin, can increase the risk of suicidal thoughts or behaviors. See the Lyrica Prescribing Information and Medication Guide for full administration and safety instructions.
    Gabapentin Enacarbil (Horizant®) –Approved for Postherpetic Neuralgia GlaxoSmithKline and Xenoport, makers of Horizant Extended-Release oral tablets, announced the June 2012 FDA approval of their extended-release gabapentin enacarbil for the adult treatment of postherpetic neuralgia. Because the pharmacokinetics of Horizant differ from other gabapentin drugs, the two products are not interchangeable. One 12-week safety and efficacy trial and 2 supportive studies in a total of 570 patients in 3 countries met primary endpoints for pain reduction. The drug is initially prescribed at 600 mg daily for 3 days, then increased to 600 mg twice daily beginning on day 4. Patients with impaired renal function must be evaluated for potential dose adjustments. The most commonly reported adverse effects were somnolence, dizziness, and headache. Dosing should be reduced for 1 week prior to discontinuation to minimize the risk of a withdrawal seizure. Healthcare providers should advise patients that antiepileptic drugs, including gabapentin enacarbil, can increase the risk of suicidal thoughts or behaviors. Horizant Extended-Release is available in 300 mg and 600 mg tablets. For complete administration and safety information, see the Medication Guide and Prescribing Information.
    Opana ER – Complete Conversion to Crush-Resistant Tablets Endo Health Solutions made a June 2012 announcement that all strengths of the original formulation of OPANA ER have been replaced by the newer crush-resistant tablet. While the tablets have been designed to resist tampering, the active ingredient oxymorphone remains the same and OPANA ER is available in 5 mg, 10 mg, 20 mg, and 30 mg dosages. The old formulation has been discontinued. The full Prescribing Information and Medication Guide can provide administration and safety data.
    Reumofan-Plus Recall — Undeclared Drug Ingredient 
    In June 2012, the FDA notified patients and healthcare professionals that Reumofan-Plus, manufactured in Mexico by Riger Naturals, contains several active pharmaceutical ingredients not shown on the label. The product is sold in retail stores and on the internet as a dietary supplement for pain relief as well as a treatment for arthritis, osteoporosis, bone cancer and other disorders. FDA laboratory analyses identified that Reumofan-Plus contained diclofenac sodium, an NSAID, which can increase the risk of gastrointestinal bleeding, ulceration, or perforation. The product also contained methocarbamol, a muscle relaxant that can cause dizziness, low blood pressure, or enough sedation to cause mental or physical impairment. Reports of adverse effects — including liver injury, sudden changes in glucose control, leg cramps, and swelling — have been reported to the FDA in association with the use of Reumofan-Plus. Healthcare providers are encouraged to ask patients who use this product to stop using it and evaluate patients for drug interactions or adverse effects. See the Recall Announcement for additional information and a MedWatch reporting form.
    eNotifications

    Don’t Miss Out. Stay Up-to-Date on Pain-Topics UPDATESJuly 2012 – Pain Product Announcements & Warnings

    Friday, 6 July 2012

    Dr. Edward Magaziner Discusses Opioids for Low Back Pain

    FDA Calls for Halt to Unapproved Drugs Containing Oxycodone


    From News Alerts > Medscape Medical News

    FDA Calls for Halt to Unapproved Drugs Containing Oxycodone

    Pauline Anderson
    Posted: 07/05/2012
     
     
    Read daily medical news on-the-go
    with Medscape’s free app.
    Learn More >
    July 5, 2012 — The US Food and Drug Administration (FDA) has issued a Federal Register notice to halt the manufacture and distribution of unapproved single-ingredient immediate-release drugs that contain oxycodone.
    Such products have not been evaluated by the FDA for safety, effectiveness, manufacturing quality, or appropriate labeling, including dosing information and warnings, and cannot be legally marketed in the United States, the FDA states in a press release.
    "It's a high public health priority for FDA to remove these unapproved products from the market to minimize consumer exposure to drugs that may be unsafe, ineffective, and of poor quality," Ilisa Bernstein, acting director of the Office of Compliance in the FDA's Center for Drug Evaluation and Research, said in the FDA statement.
    "Since FDA-approved versions of these oral dosage forms are available by prescription, there should be no negative impact on consumers as a result of this action and no disruptions to the drug supply."
    Improper labeling and use of oxycodone can lead to overdose and death. Opioid medications are associated with prescription drug misuse, abuse, and addiction, which have resulted in an increase in injuries and deaths across the United States over the last 10 years.
    Companies with products that are subject to this action are expected to stop manufacturing the products within 45 days and to stop shipping the products within 90 days. Those that continue to market products falling within the scope of this notice are subject to enforcement action, including seizure, injunction, or other judicial or administrative proceedings, according to the FDA.
    The notice is part of the FDA's Unapproved Drugs Initiative to remove unapproved drugs from the market, the statement notes.
    Healthcare professionals and consumers may report adverse side effects or medication errors from the use of prescription drug products to the FDA's MedWatch Adverse Event Reporting program at www.fda.gov/MedWatch or by calling             800-332-1088      .
     

    Monday, 2 July 2012

    NORD GRANTS

    http://www.rarediseases.org/medical-professionals/research-grants/recipients

    One one-year grant:
    Kieran Murphy, MB, BCh, FRCPC, FSIR

    Professor & Vice Chair, Medical Imaging
    University of Toronto, Ontario, Canada
    A Genetic Analysis of Patients with Tarlov Cyst Disease
    NORD's Medical Advisory Committee is in the process of reviewing five other Requests for Proposals 2012 through its international clinical research program (see Requests for Proposals/NORD Funding Opportunities for 2012).


    Sharon aka Lucky

    Monday, 25 June 2012

    www.FootDoc.caNeurology

    Neurology is the study of nerves, and this web page should give you an overview of the subject of the nerves that relate to the foot and lower extremity.  We will divide this discussion on nerves into their anatomical locations--beginning with the brain and moving downwards.  
    Communication Between The Brain & The Feet
    The brain and the feet communicate through nerve signals.  The brain sends signals down to the foot and leg to tell them to carry out an action, and the foot sends sensory signals up to the brain to give the brain information about what they are experiencing.  The signals are transmitted through the spine by what are known as Spinal Tracts.  
    Listed below are the major families of spinal tracts: 
    The major pathways extending from the foot to the brain (the afferent nerves): 
    • Spinothalamic Tract  This tract sends sensory signals to the portion of the brain that is conscious.  Light touch (like when someone touches your big toe with a cotton ball) and tickling sensations are sent up in the Anterior Spinothalamic Tract, located on the front of the spine.  Normal touch and positional sensation is sent via the Posterior Spinothalamic Tract, located on the back of the spine. Pain and temperature are sent to the brain via the Lateral Spinothalamic Tract, located on each side of the spine.  
    • Spinocerebellar Tract  This tract sends signals from the feet to the cerebellum in the lower back of the skull to give input with regards to balance (which the cerebellum controls unconsciously).
    The major pathways extending from the brain to the foot (the efferent nerves): 
    • Corticospinal Tract Also known as the Pyramidal Tract because it starts from a pyramid-shaped area of the medulla in the brain, this tract carries signals from the cortex of the brain to the muscles of the extremities.  If you wiggle your toes, you are using this tract. 
    • Extrapyramidal Tract This tract consists of those structures involving involuntary, unconscious or automatic movement of the skeletal system. If you unconsciously adjust your position while standing, for example, you are using this tract.
    • Reticulospinal Tract  This tract predominately carries autonomic function (the signals carried without your thinking about them, such as perspiration and whether to open or close the arteries) down to the extremities. 
    The Nerves of the Lower Extremity
    Nerves of the Thigh
    The nerves of the foot are all branches of one of two nerves--the Femoral Nerve, which provides only a small amount of innervation (nerve supply) to the foot), and the Sciatic Nerve, which provides the vast majority of the innervation to the foot.  
    The Femoral Nerve (pictured on the right) arises from nerve fibers from the the L2-L3-L4 portion of the lumbar spine.  (This means that the nerves leave the spinal cord beneath the 2nd, 3rd and 4th Lumbar vertebrae.)  The Femoral Nerve then passes down the inside edge of the thigh, past the inside of the knee and towards the ankle and foot.   
    The Sciatic Nerve (pictured below) is the largest nerve in the body and it is comprised of nerves from the L4-L5-S1-S2-S3 level of the spine.  (This means that the nerve fibers that make up the Sciatic Nerve leave the spinal cord beneath the fourth and fifth lumbar and the first, second and third sacral vertebrae.)  It then descends down the back of the thigh.  
    You can learn about the most common injury to the sciatic nerve by visiting our webpage on sciatica.
    The sciatic nerve passes down the back of the thigh, and near the bottom third of the thigh, it branches into two nerves:
    1. Common Peroneal Nerve, comprised of nerve fibers from L5, S1, S2, and S3.   
    2. Tibial Nerve comprised of nerve fibers from L4, L5, S1, S2 and S3)
    Each of these nerves then continues down the leg towards the knee joint.  

    Nerves Below the Knee and Above the Ankle
    Shortly after crossing the knee joint, the Common Peroneal Nerve divides into three branches--the Lateral Sural Cutaneous Nerve, the Deep Peroneal Nerve and the Superficial Peroneal Nerve.
    • The Lateral Sural Cutaneous Nerve merges with the Medial Sural Cutaneous Nerve (a branch from the Tibial Nerve described below) to form the Sural Nerve.   The Sural Nerve then runs down the outside edge of the leg.  
    • The Deep Peroneal Nerve begins at the outside edge of the upper leg, then moves across the tibia bone in the leg to supply nerve function to the muscles on the front of the leg (the Tibialis Anterior, Extensor Hallucis Longus, Extensor Digitorum Longus and Peroneus Tertius muscles).  The Deep Peroneal Nerve then continues down the leg towards the foot. 
    • The Superficial Peroneal Nerve supplies nervous function to the Peroneus Longus and Peroneus Brevis muscles, then continues down the leg.  It eventually branches into two nerves, the Medial Dorsal Cutaneous Nerve and the Intermediate Dorsal Cutaneous Nerves.  
    The first branch off the Tibial Nerve is the Medial Sural Cutaneous Nerve, which as mentioned above, connects with the Lateral Sural Cutaneous Nerve (a branch of the Common Peroneal Nerve) to form the Sural Nerve.  
    The Tibial Nerve then supplies the nervous function to the muscles in the back of the leg--the Popliteus, Gastrocnemius, Soleus, Plantaris, Tibialis Posterior, Flexor Digitorum Longus and Flexor Hallucis Longus  muscles.  The Tibial Nerve then continues down the back of the leg towards the ankle and foot.   
    Nerves of the Ankle Region and Foot
    There are five major nerves heading from the leg that impact the foot--the Sural Nerve, the Saphenous Nerve, the Tibial Nerve, the Deep Peroneal Nerve, and the Superficial Peroneal Nerve.    
    The Sural Nerve crosses behind the lateral malleolus (the bump on the outside portion of the ankle).  Once in the foot, the Sural Nerve's name changes to the Lateral Dorsal Cutaneous Nerve, and it supplies the sensory information back to the brain concerning the outside edge of the foot, including the small toe.  
    The Saphenous Nerve crosses behind the medial malleolus (the bump on the inside portion of the ankle).  This nerve retains its name and supplies the sensory information back to the brain concerning the inside edge of the foot including the small toe.
    The Posterior Tibial Nerve crosses the ankle behind the medial malleolus (the bump on the inside portion of the ankle).  It has three branches.  
    1.    Medial Calcaneal Nerve--The Medial Calcaneal Nerve is the smallest branch.  It run along the medial (inside) portion of the heel, and it provides the sensory innervation for that portion of the heel.  
    2.    Medial Plantar Nerve--The Medial Plantar Nerve is the larger of the two major nerves on the bottom of the foot.  (See diagram below.)  The fibres that make up this nerve originate at the S2-S3 level.  The Medial Plantar Nerve gives sensory perception to the bottom of the big toe, the second and third toes and half of the fourth toe, as well as the medial (inside) 2/3's of the the bottom of the foot.  This nerve provides innervation (nerve connection) with the Flexor Digitorum Brevis (FDB)Flexor Hallucis Brevis (FHB),Adductor Hallucis, and 1st Lumbrical muscles. 
    3.    Lateral Plantar Nerve--The Lateral Plantar Nerve is the smaller of the two nerves on the bottom of the foot.  (See diagram to the right.)  As with the Medial Plantar Nerve, The fibers that make up the Lateral Plantar Nerve left the spine at the S2-S3 level.  The Lateral Plantar Nerves provides sensory perception to the the outside 1/3 of the bottom of the foot, including the fifth toe and half of the fourth toe.  It innervates the Quadratus Plantae, Abductor Digiti Quinti, Flexor Digiti Quinti Brevis, 1st, 2nd, 3rd and 4th Dorsal Interossei, the 1st, 2nd and 3rd Plantar Interossei and the 2nd, 3rd and 4th Lumbrical muscles. 
    We should probably mention here that a branch from the medial plantar nerve with a branch from the lateral plantar nerve join together in the fourth interspace of the foot, and this is the primary location for a neuroma to develop.  For more information about neuromas, please visit our web page by clicking on the word neuroma.  
    The Deep Peroneal Nerve (also known as the Anterior Tibial Nerve) passes on the front of the ankle.  It divides into the medial and lateral branches.  The medial branch advances down the foot and supplies nervous sensation to the space between the big toe and second toe.  The lateral branch supplies the nervous input to the Extensor Digitorum Brevis muscle, then divides into three branches which supply the nervous input to the 2nd, 3rd and 4th Interosseous muscles. 

    Friday, 22 June 2012


    <iframe frameborder="0" height="360px" scrolling="no"
                        src="http://www.petition2congress.com/5202/first-do-no-harm-dea-targets-physicians-who-treat-their-patients/wt/?src=widget" width="220px"></iframe>

    I signed. Please join all of us who have signed and let our government know it is not OK to bully pain sufferers in their efforts, often misguided and clearly inneffective, to stem the flow of illegal drugs among criminal misusers and abusers.

    Tuesday, 12 June 2012


    Prolotherapy Arachnoiditis diagnosis inflammation
    www.prolonews.com/arachnoiditis.htmThe
    person in the above scenario needed a Prolotherapy doctor to relieve the pain, not a surgeon. Anyone carrying the diagnosis of arachnoiditis needs the ...